The investor call is scheduled for 8:30 AM Beijing Time on August 19, which corresponds to 8:30 PM U.S. Eastern Time on August 18. Everest Medicines will provide a dedicated webcast link for the Chinese-language session, alongside international dial-in numbers covering the U.S., UK, Hong Kong, Taiwan, and Singapore. The session will feature simultaneous English interpretation via a separate Zoom-based registration.
Everest Medicines Sets August 19 Date for Interim Financial Results
Shanghai-based biopharmaceutical firm Everest Medicines will release its financial results for the first half of 2026 on August 19. The company, which specializes in therapeutics for cardiovascular, kidney, and metabolic diseases, plans to host an online investor briefing to discuss its business progress and performance during the six-month period.
Everest Medicines currently maintains a broad therapeutic focus, including autoimmune, ophthalmology, and critical care treatments. The upcoming call serves as a platform for management to detail the company's progress with its proprietary mRNA platform and ongoing pipeline development. Interested parties can access the conference using the passcode 834993.
Comments (0)
No comments yet. Be the first!